FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & Everything You Need to Know About the FDA Peptide Ban FDA considers adding a dozen peptides to its bulk drug compounding list RAPS Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law